ELEKTA AB (publ)
Corporate organization number 556170-4015
Kungstensgatan 18 – Box 7593 – SE 103 93 Stockholm

Year-end report 1 May – 30 April 2006/07



- **Order bookings rose 8 percent to SEK 5,102 M (4,705). Based on unchanged exchange rates order bookings rose 15 percent. Order backlog amounted to a record high level of SEK 4,247 M.**
- **Net sales rose 2 percent to SEK 4,525 M (4,421). Based on unchanged exchange rates, net sales rose 8 percent.**
- **Operating profit amounted to SEK 509 M (453) and operating margin was 11 percent (10). Operating profit for the fourth quarter was a record high SEK 263M.**
- **Profit after taxes amounted to SEK 346 M (304). Earnings per share after dilution amounted to SEK 3.70 (3.21).**
- **Cash flow after investments was a negative SEK 107 M (158). Acquisitions are included in the amount of SEK -144 M (-195).**
- **In accordance with Elekta's distribution policy, a dividend of SEK 1.00 per share is proposed.**
- **For fiscal year 2007/08, Elekta expects a net sales growth of over 10 percent in local currency and an operating profit growth of over 30 percent.**

Elekta's operations

Elekta is an international medical technology Group, providing advanced clinical solutions, comprehensive information systems and services for efficient and high precision treatment of cancer and brain disorders. Elekta's solutions are used at over 4,000 hospitals worldwide. Elekta is the world leader in image guided and stereotactic clinical solutions for radiosurgery and radiation therapy, methods for treating tumors and functional targets with ultrahigh precision while sparing healthy tissue. The Elekta Group is also the world's largest supplier of software solutions across the spectrum of cancer care. All of Elekta's clinical solutions employ non-invasive or minimally invasive techniques. This means that in addition to being clinically effective, these solutions are also cost-effective and gentle on the patient.

Market outlook

The total market for Elekta's clinical solutions, IT systems and services is expected to grow by 5-10 percent annually and the demand remains strong. However, the high value of individual orders and order coordination within the framework of health care investment programs often lead to significant quarterly variations in business volume, product mix and geographical mix.

The market development is driven by an increased incidence of cancer and by the shortage of treatment capacity that is prevailing in most countries. New advanced, more precise and accurate methods are expected to increase the role of radiation therapy in the future. The rapid development of new technology is resulting in higher average order values. An increasing number of customers are requesting more comprehensive and long-term relationships with suppliers.

Significant events

- Elekta continues to install Elekta Synergy® for image-guided radiation therapy worldwide at a rapid pace and is steadily strengthening its leading position in this new method for treating cancer, which offers greater precision and accuracy. A clear majority of the linear accelerator orders placed to Elekta are now including technology for high resolution 3D X-ray technology.
- The market introduction of Leksell Gamma Knife® Perfexion™ has been very successful, exceeded expectations and confirmed Elekta's leadership in stereotactic radiosurgery. Both order intake and delivery volumes were high in the fourth quarter. A majority of Elekta's Gamma Knife customers during the year has opted for this advanced model and in total, Elekta has received 26 orders for Leksell Gamma Knife Perfexion. Elekta now has the full delivery capacity needed to meet an expected continued high demand.
- In August 2006, Elekta finalized the acquisition of 80 percent of Beijing Medical Equipment Institute (BMEI). This acquisition strengthens Elekta's position on the Chinese market for radiation therapy solutions and brings to Elekta the ability to meet the needs of the Chinese and other emerging markets for less capital-intensive and more affordable cancer management solutions.
- In May 2007, Elekta finalized the acquisition of the Italian company 3D Line Research and Development S.r.l., adding to Elekta a highly qualified R&D group specialized in stereotactic radiosurgery and dynamic IMRT treatments as well as a product portfolio of advanced equipment and treatment planning software systems for performing radiation therapy with extreme precision and optimized dose distribution.

Order bookings and order backlog

Order bookings rose 8 percent to SEK 5,102 M (4,705). Elekta BMEI, acquired in August 2006, contributed SEK 14 M. Based on unchanged exchange rates order bookings rose 15 percent.

Based on unchanged exchange rates order bookings in North and South America rose 16 percent, region Europe, including Middle East and Africa, rose 18 percent and Asia rose 6 percent.

Order booking rose 1 percent during the fourth quarter to SEK 1,563 M (1,543).

Order backlog on April 30, 2007, was at an all time high level of SEK 4,247 M (3,875).



Order bookings SEK M	Quarter 4 2006/07	Quarter 4 2005/06	Change	12 months 2006/07	12 months 2005/06	Change
Europe, Middle East, Africa	532	619	-14%	1,997	1,711	17%
North and South America	776	687	13%	2,307	2,169	6%
Asia	255	237	8%	798	825	-3%
Group	**1,563**	**1,543**	**1%**	**5,102**	**4,705**	**8%**

Market comments

North and South America

The North American market continues to show healthy growth, primarily driven by the rising cancer incidence and by the rapid acceptance of new and refined treatment methods such as image guided radiation therapy (IGRT) and stereotactic radiation therapy (SRT).

Elekta's leadership in image guided radiation therapy, combined with Elekta's ability to supply treatment equipment and information management systems as one comprehensive and integrated offer, have substantially strengthened Elekta's position on the North American market.

Virtually all linear accelerator orders placed to Elekta from North America are now including technology for high resolution 3D X-ray technology.

Elekta is the market leader in the segment for stereotactic radiation therapy and radiosurgery (SRS/SRT) which is expected to grow rapidly in the coming years. The market introduction of Leksell Gamma Knife® Perfexion™ has been met with high interest from both current Gamma Knife users and new potential customers. Through the launch of Elekta Axesse™, Elekta is now also offering a complete and multifunctional treatment system for all applications of SRS/SRT.

In the US market, efficiency in patient flows and processing of clinical data are often decisive sales arguments. Software systems that handle both the entire treatment process and administration and resource allocation are therefore in most cases an integrated part of the delivery of treatment systems.

Europe including Middle East and Africa

Elekta's position in the European market for radiation therapy is strong. The European market is driven primarily by the lack of care capacity and therapeutic equipment. In many European countries, the number of linear accelerators per capita is less than half that of the US.

Several countries are showing interest in different forms of private financing of public care, similar to the Private Financing Initiative (PFI) model that has been established in the UK. Elekta's ability to provide comprehensive and integrated solutions, yet based on industry standards and open connectivity, makes the company an attractive partner in such projects.

In Western Europe, the number of large coordinated investments in new treatment capacity during fiscal year 2006/07 has been lower than in preceding years and the total market activity has thus been lower. In 2007/08, the market is expected to show good growth.

There is a substantial demand in Europe for information systems for cancer care, particularly for the purpose of improving productivity, streamlining operations and multi-site connectivity. Elekta continues therefore to introduce IMPAC systems on more markets in Europe, at a pace deemed suitable taking into account installation and service resources.

Asia

In China, the healthcare system is currently undergoing reform and restructuring, in order to meet the growing need for advanced care and to make these services more accessible to a lager share of the population. This has caused the long-standing market growth in China to weaken temporarily and the market to decline, compared to previous year. During the spring of 2007, the number of tender requests has increased.

Elekta is the market leader in China in the segment for advanced radiation therapy solutions. The acquisition of 80 percent of Beijing Medical Equipment Institute (BMEI) will further strengthen Elekta's position on the Chinese market.

Long-term, there is a solid rationale for a continued rapid economic growth in China and other Asian countries. The number of linear accelerators in the country is approximately 0.6 per million inhabitants and in countries such as India, the Philippines and Indonesia, this number is even lower. Through market leadership in the advanced segment and new offerings under development in the newly acquired Elekta BMEI, Elekta is well positioned to meet continued strong demand in the region and to support health care providers in these countries in their quest to develop cancer care.

In Japan, there is a large installed base of Leksell Gamma Knife and subsequently, there is substantial potential for upgrades to Leksell Gamma Knife Perfexion. Due to the long process for regulatory approval in Japan, Elekta does not expect to be able to introduce this new system until late in the fiscal year 2007/08. During fiscal year 2006/07, Elekta has invested in radiation therapy reference centers in Japan and the company expects to be able to increase market share on the linear accelerator market.

Several countries in the region, including India and Australia, show good growth and Elekta gradually strengthens its position on these markets.

Aftermarket

Elekta's aftermarket is continuing to show favorable development, partly as a result of a growing installed base. The shift towards more advanced, newly launched systems is resulting in more customers choosing comprehensive service agreements.

Elekta continues to focus on further development of support and lifecycle business and on providing value-based services to the expanding customer base.

Net sales

Net sales rose 2 percent to SEK 4,525 M (4,421). Elekta BMEI, acquired in August 2006, contributed SEK 23 M. Based on unchanged exchange rate, net sales rose 8 percent.

Net sales rose during the fourth quarter to SEK 1,443 M (1,384).



Net sales SEK M	Quarter 4 2006/07	Quarter 4 2005/06	Change	12 months 2006/07	12 months 2005/06	Change
Europe, Middle East, Africa	619	463	34%	1,840	1,608	14%
North and South America	640	621	3%	1,933	1,971	-2%
Asia	184	300	-39%	752	842	-11%
Group	**1,443**	**1,384**	**4%**	**4,525**	**4,421**	**2%**

Earnings

Operating profit rose 12 percent to SEK 509 M (453), positively impacted by increased delivery volumes and lower amortization of intangibles and negatively by currency movements.

Gross margin amounted to 41 percent (42). Operating margin was 11 percent (10).

Operating profit during the fourth quarter amounted to a record high SEK 263 M (201), primarily as a result of increased net sales. Operating margin was 18 percent (15).

The calculated IFRS 2 (Share-based payment) costs for Elekta's outstanding option programs amounted to SEK 22 M (20).

Investments in research and development rose 11 percent to SEK 374 M (337) equal to 8 percent (8) of net sales. Capitalization of development costs and amortization of capitalized development costs affected earnings in the amount of SEK 14 M (20). Capitalization amounted to SEK 27 M (32) and amortization to SEK 13 M (12).

Exchange rate effects on operating profit compared with preceding year:

- Exchange rate movements affected operating profit before recorded exchange differences negatively by about SEK 106 M.
- Recorded exchange gains in operations amounted to SEK 35 M.
- Recorded exchange losses in operations preceding year was SEK 35 M.

In total, exchange rate fluctuations 2006/07 compared with the preceding year affected operating profit negatively by SEK 36 M.

Currency hedging is done on the basis of anticipated sales in foreign currency over a period of up to 24 months. Exchange rate gains from forward contracts in operating profit amounted to SEK 63 M (loss: 27). Unrealized exchange rate gains from cash flow hedges amounted to SEK 18 M and are reported in shareholders' equity, taking into account the tax effect.



Net financial items amounted to a loss of SEK 2 M (loss: 9). Net interest expenses amounted to SEK 25 M (31). Shares in the earnings of associated companies amounted to SEK 17 M (15) and financial exchange rate gains to SEK 6 M (7).

Profit after net financial items rose to SEK 507 M (444). Tax expense for 2006/07 amounted to SEK 161 M and was positively affected by adjustments regarding prior years. Profit after taxes amounted to SEK 346 M (304).

Earnings per share amounted to SEK 3.72 (3.23) before dilution and SEK 3.70 (3.21) after dilution.

Return on shareholders' equity amounted to 19 percent (17) and return on capital employed was 20 percent (18).

Investments and depreciation

The acquisition of BMEI resulted in an increase in intangible and tangible fixed assets of SEK 170 M. Other investments in intangible and tangible assets amounted to SEK 153 M (187). Amortization of intangible and depreciation of tangible assets amounted to SEK 136 M (171).

Liquidity and financial position

Cash flow from operating activities was positive SEK 150 M (pos: 498). Working capital increased due to high delivery volumes late in the fourth quarter. This together with a change in geographical mix resulted in an increase in trade receivables by SEK 345 M to SEK 1,261 M. Cash flow after investments was a negative SEK 107 M (neg. 158). Acquisitions were included in the amount of SEK 144 M (195).

Liquid funds amounted on April 30, 2007 to SEK 484 M (981). SEK 9 M of bank balances was pledged primarily for commercial guarantees.

Interest-bearing liabilities amounted on April 30, 2007 to SEK 987 M (1,091). Net debt amounted to SEK 503 M (110).

Net debt/equity ratio was 0.27 and equity/assets ratio was 35 percent.

During May-April 2006/07, 264,621 new Series B shares were subscribed through the exercise of warrants distributed within the framework of the established option program.

801.700 shares repurchased during June-July 2006 were cancelled following the approval of the Annual General Meeting.

During the period March 12 through March 16, 2007, Elekta repurchased 759,271 B shares at an average price of SEK 131.65 totaling SEK 99,958,778. Accordingly, Elekta's current holding of own shares (treasury stock) amounts to 759,271 B shares, which Elekta's Board intends to propose to the AGM to be cancelled.

On May 31, 2007, the total number of shares was 93,794,776.

Employees

The average number of employees was 1,951 (1,750).

The number of employees on April 30, 2007 totaled 2,031 compared with 1,812 on April 30, 2006. The increase was primarily a result of the acquisition of BMEI.

Parent Company

The operations of the Parent Company include Group management and Group-wide functions, as well as financial administration. The Parent Company's profit after net financial items amounted to SEK 38 M (profit: 19). The average number of employees was 20 (21).

Acquisition of BMEI

Elekta's acquisition of 80 percent of the equity of the Chinese provider of radiation therapy equipment, Beijing Medical Equipment Institute (BMEI) and the transformation of the company into a Joint Venture (JV) was finalized, after the business license was granted by the Beijing Administration for Industry and Commerce on August 18, 2006. The acquisition value including direct acquisition costs amounted to SEK 149 M.

BMEI's registered office is in Chang Ping, a suburb north of Beijing, and at time of acquisition had 146 employees.

The initial accounting for the fair values to be assigned to the acquired unit's identifiable assets and liabilities has been provisionally established. Intangible assets and goodwill have been valued at SEK 130 M. The intangible assets consist of technology under development and the amortization period is five years. Goodwill refers primarily to future synergy effects.

The acquisition enables Elekta to meet the needs of the Chinese and other developing markets for less capital-intensive equipment for radiation therapy. Elekta plans to develop the operations of BMEI through investments in research and development, production capacity and infrastructure.

Net sales from date of acquistion to end of April 2007 amounted to SEK 23 M and the operating loss amounted to SEK 7 M.

Acquisition of 3D Line

In May 2007, Elekta acquired 3D Line Research and Development (3D Line), adding to Elekta a highly qualified R&D group specialized in stereotactic radiosurgery and dynamic IMRT treatments as well as a product portfolio of advanced equipment and treatment planning software systems for performing radiation therapy with extreme precision and optimized dose distribution.

In May, Elekta paid 10 million Euro in cash for 3D Line. The purchase agreement contains also an earn-out maximized to 8 million Euro, dependent on the company's performance during the coming 3 years.

3D Line's registered office is in Milan, Italy and at time of acquisition had 20 employees.

Future prospects for fiscal year 2007/08

Demand for Elekta's clinical solutions, products and services remains strong. The order backlog is on a record high level. The product portfolio is broader and more competitive than ever before.

For fiscal year 2007/08, Elekta foresees a net sales growth exceeding 10 percent, in local currency.

Elekta's leading position in IGRT, combined with the newly launched systems for stereotactic radiation therapy and stereotactic radiosurgery, is shifting the product mix towards more advanced systems.

During fiscal year 2007/08, operating profit is expected to grow over 30 percent, primarily driven by product mix changes and operating leverage. Net sales and operating profit is expected to be higher in the second half of the fiscal year, compared with the first half.

Changes in currency exchange rates may affect Elekta's ability to reach its targets.

Dividend and proposal to repurchase shares

Elekta's goal is to provide shareholders with a favorable return and value growth. According to the company's dividend policy, the goal is to distribute 20 percent or more of net profit to the shareholders in the form of dividends, share repurchases or comparable measures. Decisions regarding dividend payments are based on Elekta's financial position, the expected profitability trend, growth potential and investment needs.

For fiscal years 2004/05 and 2005/06 respectively, dividend together with share repurchases in the following years, has corresponded to 86 percent and 97 percent of net profit, in line with the company's ambition to create shareholder value.

In accordance with the company's dividend policy, the Board proposes a dividend of SEK 1.00 per share, corresponding to approx. SEK 93 M and 27 percent of net profit.

The Board also intends to propose to the Annual General Meeting on September 25, 2007 a new authorization for the Board to repurchase a maximum of 10 percent of the number of shares outstanding in Elekta AB. The decision on repurchases will be made during the year based on the share price performance, Elekta's financial position, profitability trend and investment needs.

Annual General Meeting

The Annual General Meeting will be held on Tuesday, September 25, 2007 at 3:00 p.m. at the Polstjärnan Konferens, Sveavägen 77, Stockholm.

Financial information

The annual report for 2006/07 is scheduled for publication on September 11, 2007.
Interim report for May-July 2007/08 will be published on September 25, 2007.

Stockholm June 14, 2007

Elekta AB (publ)

Tomas Puusepp
President & CEO

The Company's auditors have not reviewed this interim report.

For further information, please contact:

Peter Ejemyr, Group Vice President Corporate Communications, Elekta AB (publ)
Tel: +46 733-611 000 (mobile), e-mail: peter.ejemyr@elekta.com

For more information on Elekta, please visit www.elekta.com

Capital Markets Day with webcast and call-in option

Elekta will hold a Capital Markets Day today, June 14, from 3 pm to approx. 6 pm. This event will be held at Elekta's head office on Kungstensgatan 18, in central Stockholm.

Remote attendance details:
The Capital Markets Day on June 14, will be broadcasted over the Internet (audio and slides). Please visit http://www.elekta.com/investors and follow the link or use the direct link: http://events.webeventservices.com/elekta/2007/06/14/

It will also be possible to dial in and listen to this event:

- Swedish dial-in number: +46 (0)8 505 20 110
- UK dial-in number: +44 (0)20 7162 0025
- US dial-in number: +1 334 323 6201

Password: Elekta (NOTE: for Local Connect dial-in numbers – you may have to dial the area code to enter the conference.) Dial-in participants can watch slides on the web (see link above). No telephone Q&A session will be held. Remote participants can instead e-mail questions to ir@elekta.com during the event. The slide package will be distributed upon request after the event. If you wish to receive the slides, please send an e-mail to ir@elekta.com.

A replay of the event will be available until June 22, 2007. Please use the same link as above or call the numbers below and give the access code 750274.

- Swedish replay number: +46 (0)8 505 203 33
- UK replay number: +44 (0) 207 031 4064
- US replay number: +1 954 334 0342

Accounting principles

This interim report has been prepared in accordance with the Annual Accounts Act, IAS 34 Interim Financial Reporting and the Swedish Financial Accounting Standards Council's recommendation RR 31 Interim Reporting for Groups and, with regard to the Parent Company, RR 32 Accounting for legal entities. Applied accounting principles and calculation methods are in accordance with the Annual Report for 2005/06.

Exchange rates		**Average rate**			**Closing rate**		
Country	Currency	May-Apr. 2006/07	May-Apr. 2005/06	Change	Apr. 30, 2007	Apr. 30, 2006	Change
Euro	1 EUR	9.205	9.365	-2%	9.159	9.299	-2%
Great Britain	1 GBP	13.604	13.710	-1%	13.423	13.363	0%
Japan	100 JPY	6.087	6.782	-10%	5.635	6.485	-13%
United States	1 USD	7.120	7.728	-8%	6.738	7.413	-9%

INCOME STATEMENT

SEK M	3 months Feb. - Apr. 2006/07	3 months Feb. - Apr. 2005/06	12 months May - Apr. 2006/07	12 months May - Apr. 2005/06
Net sales	1,443	1,384	4,525	4,421
Cost of products sold	-841	-807	-2,648	-2,579
Gross income	602	577	1,877	1,842
Selling expenses	-163	-166	-613	-640
Administrative expenses	-105	-109	-430	-397
R&D expenses	-97	-87	-360	-317
Exchange differences in operation	26	-14	35	-35
Operating profit	**263**	**201**	**509**	**453**
Result from participations in associated companies	- 2	2	17	15
Interest income	12	11	46	28
Interest expenses	- 19	- 15	-71	-59
Financial exchange differences	- 1	0	6	7
Income after financial items	**253**	**199**	**507**	**444**
Taxes	- 90	- 62	-161	-140
Net income	**163**	**137**	**346**	**304**
Attributable to				
Parent Company shareholders	164	137	348	304
Minority shareholders	- 1	0	- 2	0
Earnings per share before dilution	1.76	1.46	3.72	3.23
Earnings per share after dilution	1.75	1.45	3.70	3.21

CASH FLOW

	3 months Feb. - Apr. 2006/07	3 months Feb. - Apr. 2005/06	12 months May - Apr. 2006/07	12 months May - Apr. 2005/06
Operating cash flow	244	193	485	457
Change in working capital	4	131	-335	41
Cash flow from operating activities	**248**	**324**	**150**	**498**
Investments and disposals	-31	-29	-257	-340
Cash flow after investments	**217**	**295**	**-107**	**158**
External financing	-122	14	-373	67
Change in liquid funds	90	306	-497	237

BALANCE SHEET

SEK M	Apr. 30, 2007	Apr. 30, 2006
Intangible assets	2,198	2,182
Tangible fixed assets	252	230
Financial fixed assets	32	26
Inventories	423	364
Receivables	1,967	1,501
Liquid assets	484	981
Total assets	**5,356**	**5,284**
Shareholders' equity	1,863	1,868
Provisions	323	322
Interest-bearing liabilities	987	1,091
Interest-free liabilities	2,183	2,003
Total shareholders' equity, provisions and liabilities	**5,356**	**5,284**
Assets pledged	9	35
Contingent liabilities	89	127

CHANGES IN SHAREHOLDERS' EQUITY

SEK M	Apr. 30, 2007	Apr. 30, 2006
Opening balance	1,868	1,694
Changed accounting principle		11
IFRS 2 cost and deferred tax	18	25
IAS 39 unrealized cash flow hedges	6	-3
Translation differences	-106	25
Net income	346	304
Option premiums and warrants exercised	16	19
Repurchase of shares	-200	
Dividend	-93	-207
Minority's capital contribution	8	
Closing balance	1,863	1,868

KEY FIGURES

	12 months May - Apr. 2003/04	12 months May - Apr. 2004/05	12 months May - Apr. 2004/05*	12 months May - Apr. 2005/06	12 months May - Apr. 2006/07
Order bookings, SEK M	3,262	3,558	3,558	4,705	5,102
Net sales, SEK M	2,900	3,152	3,152	4,421	4,525
Operating result, SEK M	306	349	364	453	509
Operating margin	11%	11%	12%	10%	11%
Profit margin	11%	12%	12%	10%	11%
Shareholders' equity, SEK M	1,413	1,674	1,694	1,868	1,863
Capital employed, SEK M	1,644	2,507	2,527	2,959	2,850
Equity/assets ratio	46%	37%	38%	35%	35%
Net debt/equity ratio	-0.65	0.05	0.05	0,06	0,27
Return on shareholders' equity	17%	16%	16%	17%	19%
Return on capital employed	20%	20%	21%	18%	20%

* Restated according to IFRS.

DATA PER SHARE

	12 months May - Apr. 2003/04	12 months May - Apr. 2004/05	12 months May - Apr. 2004/05*	12 months May - Apr. 2005/06	12 months May - Apr. 2006/07
Earnings per share					
before dilution, SEK	2.54	2.56	2.69	3.23	3.72
after dilution, SEK	2.54	2.56	2.69	3.21	3.70
Cash flow per share					
before dilution, SEK	3.71	-11.09	-11,09	1.68	-1.14
after dilution, SEK	3.71	-11.06	-11,06	1.67	-1.14
Shareholders' equity per share					
before dilution, SEK	15.16	17.80	18.02	19.80	19.95
after dilution, SEK	15.44	18.63	18.84	20.45	20.44
Average number of shares					
before dilution, 000s	97,756	93,991	93,991	94,136	93,698
after dilution, 000s	97,756	94,182	94,182	94,785	94,249
Number of shares at closing					
before dilution, 000s	93,199	94,028	94,028	94,332	93,036
after dilution, 000s	93,199	95,703	95,703	95,703	94,072

* Restated according to IFRS.
Dilution in 2003/04 refers to warrants program 2000/2003.
Dilution in 2004/05-2006/07 refers to warrants program 2004/2008.
All historical data restated for split 3:1 October 2005.